1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Immunotherapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Tumor Infiltrating Lymphocyte (TIL) Treatment
1.2.3 Engineered T Cell Receptor (TCR) Therapy
1.2.4 Chimeric Antigen Receptor (CAR) T Cell Therapy
1.2.5 Natural Killer (NK) Cell Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Tumor Immunotherapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Biopharmaceutical Company
1.3.3 Hospital
1.3.4 Universities And Other Scientific Research Institutions
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered 2 Global Growth Trends
2.1 Global Tumor Immunotherapy Market Perspective (2017-2028)
2.2 Tumor Immunotherapy Growth Trends by Region
2.2.1 Tumor Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Tumor Immunotherapy Historic Market Size by Region (2017-2022)
2.2.3 Tumor Immunotherapy Forecasted Market Size by Region (2023-2028)
2.3 Tumor Immunotherapy Market Dynamics
2.3.1 Tumor Immunotherapy Industry Trends
2.3.2 Tumor Immunotherapy Market Drivers
2.3.3 Tumor Immunotherapy Market Challenges
2.3.4 Tumor Immunotherapy Market Restraints 3 Competition Landscape by Key Players
3.1 Global Top Tumor Immunotherapy Players by Revenue
3.1.1 Global Top Tumor Immunotherapy Players by Revenue (2017-2022)
3.1.2 Global Tumor Immunotherapy Revenue Market Share by Players (2017-2022)
3.2 Global Tumor Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tumor Immunotherapy Revenue
3.4 Global Tumor Immunotherapy Market Concentration Ratio
3.4.1 Global Tumor Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunotherapy Revenue in 2021
3.5 Tumor Immunotherapy Key Players Head office and Area Served
3.6 Key Players Tumor Immunotherapy Product Solution and Service
3.7 Date of Enter into Tumor Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans 4 Tumor Immunotherapy Breakdown Data by Type
4.1 Global Tumor Immunotherapy Historic Market Size by Type (2017-2022)
4.2 Global Tumor Immunotherapy Forecasted Market Size by Type (2023-2028) 5 Tumor Immunotherapy Breakdown Data by Application
5.1 Global Tumor Immunotherapy Historic Market Size by Application (2017-2022)
5.2 Global Tumor Immunotherapy Forecasted Market Size by Application (2023-2028) 6 North America
6.1 North America Tumor Immunotherapy Market Size (2017-2028)
6.2 North America Tumor Immunotherapy Market Size by Type
6.2.1 North America Tumor Immunotherapy Market Size by Type (2017-2022)
6.2.2 North America Tumor Immunotherapy Market Size by Type (2023-2028)
6.2.3 North America Tumor Immunotherapy Market Share by Type (2017-2028)
6.3 North America Tumor Immunotherapy Market Size by Application
6.3.1 North America Tumor Immunotherapy Market Size by Application (2017-2022)
6.3.2 North America Tumor Immunotherapy Market Size by Application (2023-2028)
6.3.3 North America Tumor Immunotherapy Market Share by Application (2017-2028)
6.4 North America Tumor Immunotherapy Market Size by Country
6.4.1 North America Tumor Immunotherapy Market Size by Country (2017-2022)
6.4.2 North America Tumor Immunotherapy Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada 7 Europe
7.1 Europe Tumor Immunotherapy Market Size (2017-2028)
7.2 Europe Tumor Immunotherapy Market Size by Type
7.2.1 Europe Tumor Immunotherapy Market Size by Type (2017-2022)
7.2.2 Europe Tumor Immunotherapy Market Size by Type (2023-2028)
7.2.3 Europe Tumor Immunotherapy Market Share by Type (2017-2028)
7.3 Europe Tumor Immunotherapy Market Size by Application
7.3.1 Europe Tumor Immunotherapy Market Size by Application (2017-2022)
7.3.2 Europe Tumor Immunotherapy Market Size by Application (2023-2028)
7.3.3 Europe Tumor Immunotherapy Market Share by Application (2017-2028)
7.4 Europe Tumor Immunotherapy Market Size by Country
7.4.1 Europe Tumor Immunotherapy Market Size by Country (2017-2022)
7.4.2 Europe Tumor Immunotherapy Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries 8 Asia-Pacific
8.1 Asia-Pacific Tumor Immunotherapy Market Size (2017-2028)
8.2 Asia-Pacific Tumor Immunotherapy Market Size by Type
8.2.1 Asia-Pacific Tumor Immunotherapy Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Tumor Immunotherapy Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Tumor Immunotherapy Market Share by Type (2017-2028)
8.3 Asia-Pacific Tumor Immunotherapy Market Size by Application
8.3.1 Asia-Pacific Tumor Immunotherapy Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Tumor Immunotherapy Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Tumor Immunotherapy Market Share by Application (2017-2028)
8.4 Asia-Pacific Tumor Immunotherapy Market Size by Region
8.4.1 Asia-Pacific Tumor Immunotherapy Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Tumor Immunotherapy Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia 9 Latin America
9.1 Latin America Tumor Immunotherapy Market Size (2017-2028)
9.2 Latin America Tumor Immunotherapy Market Size by Type
9.2.1 Latin America Tumor Immunotherapy Market Size by Type (2017-2022)
9.2.2 Latin America Tumor Immunotherapy Market Size by Type (2023-2028)
9.2.3 Latin America Tumor Immunotherapy Market Share by Type (2017-2028)
9.3 Latin America Tumor Immunotherapy Market Size by Application
9.3.1 Latin America Tumor Immunotherapy Market Size by Application (2017-2022)
9.3.2 Latin America Tumor Immunotherapy Market Size by Application (2023-2028)
9.3.3 Latin America Tumor Immunotherapy Market Share by Application (2017-2028)
9.4 Latin America Tumor Immunotherapy Market Size by Country
9.4.1 Latin America Tumor Immunotherapy Market Size by Country (2017-2022)
9.4.2 Latin America Tumor Immunotherapy Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil 10 Middle East & Africa
10.1 Middle East & Africa Tumor Immunotherapy Market Size (2017-2028)
10.2 Middle East & Africa Tumor Immunotherapy Market Size by Type
10.2.1 Middle East & Africa Tumor Immunotherapy Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Tumor Immunotherapy Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Tumor Immunotherapy Market Share by Type (2017-2028)
10.3 Middle East & Africa Tumor Immunotherapy Market Size by Application
10.3.1 Middle East & Africa Tumor Immunotherapy Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Tumor Immunotherapy Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Tumor Immunotherapy Market Share by Application (2017-2028)
10.4 Middle East & Africa Tumor Immunotherapy Market Size by Country
10.4.1 Middle East & Africa Tumor Immunotherapy Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Tumor Immunotherapy Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE 11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Tumor Immunotherapy Introduction
11.1.4 Roche Revenue in Tumor Immunotherapy Business (2017-2022)
11.1.5 Roche Recent Developments
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Tumor Immunotherapy Introduction
11.2.4 Merck Revenue in Tumor Immunotherapy Business (2017-2022)
11.2.5 Merck Recent Developments
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Tumor Immunotherapy Introduction
11.3.4 Novartis Revenue in Tumor Immunotherapy Business (2017-2022)
11.3.5 Novartis Recent Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Tumor Immunotherapy Introduction
11.4.4 Johnson & Johnson Revenue in Tumor Immunotherapy Business (2017-2022)
11.4.5 Johnson & Johnson Recent Developments
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Tumor Immunotherapy Introduction
11.5.4 GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2017-2022)
11.5.5 GlaxoSmithKline Recent Developments
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Tumor Immunotherapy Introduction
11.6.4 AbbVie Revenue in Tumor Immunotherapy Business (2017-2022)
11.6.5 AbbVie Recent Developments
11.7 ELI Lilly
11.7.1 ELI Lilly Company Details
11.7.2 ELI Lilly Business Overview
11.7.3 ELI Lilly Tumor Immunotherapy Introduction
11.7.4 ELI Lilly Revenue in Tumor Immunotherapy Business (2017-2022)
11.7.5 ELI Lilly Recent Developments
11.8 Amgen
11.8.1 Amgen Company Details
11.8.2 Amgen Business Overview
11.8.3 Amgen Tumor Immunotherapy Introduction
11.8.4 Amgen Revenue in Tumor Immunotherapy Business (2017-2022)
11.8.5 Amgen Recent Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Company Details
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Tumor Immunotherapy Introduction
11.9.4 AstraZeneca Revenue in Tumor Immunotherapy Business (2017-2022)
11.9.5 AstraZeneca Recent Developments
11.10 Bristol-Mysers Squibb
11.10.1 Bristol-Mysers Squibb Company Details
11.10.2 Bristol-Mysers Squibb Business Overview
11.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Introduction
11.10.4 Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2017-2022)
11.10.5 Bristol-Mysers Squibb Recent Developments
11.11 Kite Pharma
11.11.1 Kite Pharma Company Details
11.11.2 Kite Pharma Business Overview
11.11.3 Kite Pharma Tumor Immunotherapy Introduction
11.11.4 Kite Pharma Revenue in Tumor Immunotherapy Business (2017-2022)
11.11.5 Kite Pharma Recent Developments
11.12 Adaptimmune
11.12.1 Adaptimmune Company Details
11.12.2 Adaptimmune Business Overview
11.12.3 Adaptimmune Tumor Immunotherapy Introduction
11.12.4 Adaptimmune Revenue in Tumor Immunotherapy Business (2017-2022)
11.12.5 Adaptimmune Recent Developments
11.13 Altor Bioscience Corporation
11.13.1 Altor Bioscience Corporation Company Details
11.13.2 Altor Bioscience Corporation Business Overview
11.13.3 Altor Bioscience Corporation Tumor Immunotherapy Introduction
11.13.4 Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2017-2022)
11.13.5 Altor Bioscience Corporation Recent Developments
11.14 Cellectis
11.14.1 Cellectis Company Details
11.14.2 Cellectis Business Overview
11.14.3 Cellectis Tumor Immunotherapy Introduction
11.14.4 Cellectis Revenue in Tumor Immunotherapy Business (2017-2022)
11.14.5 Cellectis Recent Developments
11.15 Juno Therapeutics
11.15.1 Juno Therapeutics Company Details
11.15.2 Juno Therapeutics Business Overview
11.15.3 Juno Therapeutics Tumor Immunotherapy Introduction
11.15.4 Juno Therapeutics Revenue in Tumor Immunotherapy Business (2017-2022)
11.15.5 Juno Therapeutics Recent Developments
11.16 Takara Bio
11.16.1 Takara Bio Company Details
11.16.2 Takara Bio Business Overview
11.16.3 Takara Bio Tumor Immunotherapy Introduction
11.16.4 Takara Bio Revenue in Tumor Immunotherapy Business (2017-2022)
11.16.5 Takara Bio Recent Developments
11.17 Unum Therapeutics
11.17.1 Unum Therapeutics Company Details
11.17.2 Unum Therapeutics Business Overview
11.17.3 Unum Therapeutics Tumor Immunotherapy Introduction
11.17.4 Unum Therapeutics Revenue in Tumor Immunotherapy Business (2017-2022)
11.17.5 Unum Therapeutics Recent Developments
11.18 Sunway
11.18.1 Sunway Company Details
11.18.2 Sunway Business Overview
11.18.3 Sunway Tumor Immunotherapy Introduction
11.18.4 Sunway Revenue in Tumor Immunotherapy Business (2017-2022)
11.18.5 Sunway Recent Developments
11.19 Junshi Bio
11.19.1 Junshi Bio Company Details
11.19.2 Junshi Bio Business Overview
11.19.3 Junshi Bio Tumor Immunotherapy Introduction
11.19.4 Junshi Bio Revenue in Tumor Immunotherapy Business (2017-2022)
11.19.5 Junshi Bio Recent Developments
11.20 Cinda Bio
11.20.1 Cinda Bio Company Details
11.20.2 Cinda Bio Business Overview
11.20.3 Cinda Bio Tumor Immunotherapy Introduction
11.20.4 Cinda Bio Revenue in Tumor Immunotherapy Business (2017-2022)
11.20.5 Cinda Bio Recent Developments
11.21 BeiGene
11.21.1 BeiGene Company Details
11.21.2 BeiGene Business Overview
11.21.3 BeiGene Tumor Immunotherapy Introduction
11.21.4 BeiGene Revenue in Tumor Immunotherapy Business (2017-2022)
11.21.5 BeiGene Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
